GeneDx Holdings Corp. Class A Common Stock
WGS
$77.08
+10.76%
GeneDx Holdings Corp. is a genomics company focused on exome and genome sequencing for rare and ultra-rare pediatric genetic disorders, operating in the healthcare information services industry. As a pioneer in whole exome and genome sequencing, GeneDx aims to make genomic testing the standard of care for diagnosing genetic diseases, positioning itself as a leader in precision medicine. The current investor narrative centers on the company's rapid revenue growth and path to profitability, driven by expanding insurance coverage and increasing adoption of its diagnostic tests, though the stock has experienced significant volatility amid broader market sentiment and operational transitions.…
WGS
GeneDx Holdings Corp. Class A Common Stock
$77.08
Investment Opinion: Should I buy WGS Today?
Rating: Buy. GeneDx offers a high-growth opportunity with a clear path to profitability, supported by strong analyst consensus (Strong Buy, average target $81.78) and a 15.3% upside. The company's revenue growth of 26.5% YoY, gross margin expansion to 65.2%, and positive TTM FCF of $14.26M provide a solid foundation for continued improvement. The PS ratio of 8.18x is elevated but justified by the growth rate, and the forward PE of 64.24x reflects expected earnings growth. Key risks include valuation compression if growth decelerates, competitive pressures, and execution risk in achieving sustained profitability. This Buy rating would be downgraded to Hold if revenue growth falls below 15% or if gross margins decline below 60%, and upgraded to Strong Buy if the stock pulls back to below $60 while fundamentals remain intact. Overall, the stock is fairly valued relative to its growth potential, but investors should be prepared for high volatility.
Sign up to view all
WGS 12-Month Price Forecast
The AI model assesses GeneDx as bullish over the next 12 months, driven by strong revenue growth, improving margins, and a clear path to profitability. The high beta and volatility are concerns, but the fundamental improvements and analyst support outweigh the risks. The stance would be upgraded to high confidence if the company achieves two consecutive quarters of positive net income, and downgraded to neutral if revenue growth falls below 15% or if gross margins drop below 60%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GeneDx Holdings Corp. Class A Common Stock's 12-month outlook, with a consensus price target around $85.89 and implied upside of +11.4% versus the current price.
Average Target
$85.89
0 analysts
Implied Upside
+11.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$63 - $103
Analyst target range
Analyst coverage is limited but bullish, with 9 analysts covering the stock and a consensus recommendation of 'Strong Buy' (mean rating 1.11). The average target price is $81.78, implying approximately 15.3% upside from the current price of $70.90. The target range spans from $63.00 (low) to $100.00 (high), indicating a wide dispersion of expectations. The high target suggests optimism about continued revenue growth and margin expansion, while the low target reflects concerns about competitive pressures and potential setbacks. Recent ratings actions have been positive, with Wells Fargo upgrading from Equal Weight to Overweight in February 2026, and other firms maintaining Buy ratings, signaling growing institutional confidence.
Drowning in data?
Find the real signal!
Bulls vs Bears: WGS Investment Factors
GeneDx presents a compelling growth story with accelerating revenue, expanding margins, and a clear path to profitability, supported by a Strong Buy analyst consensus. However, the stock's extreme volatility, high valuation, and history of losses introduce significant risk. Currently, the bull case has stronger evidence given the fundamental improvements and positive analyst sentiment, but the bear case hinges on valuation and execution risk. The key tension is whether the company can sustain its growth trajectory and achieve profitability before market sentiment turns against its premium multiple.
Bullish
- Revenue growth accelerating: Q4 2025 revenue of $120.99M grew 26.5% YoY, up from $102.69M in Q2 2025 and $87.12M in Q1 2025, showing consistent sequential acceleration. This indicates strong demand for exome/genome testing and expanding insurance coverage.
- Gross margin expansion to 65.2%: Gross margin improved from 60.9% in Q2 2024 to 65.2% in Q4 2025, reflecting better cost management and scale. This trend supports the path to profitability and justifies a premium valuation.
- Narrowing losses and positive FCF: Net loss narrowed from -$29.17M in Q2 2024 to -$17.67M in Q4 2025, with net margin improving from -41.4% to -14.6%. TTM free cash flow turned positive at $14.26M, indicating the company is approaching self-sufficiency.
- Strong analyst consensus and upside: With 9 analysts, consensus is Strong Buy (mean 1.11) and average target $81.78, implying 15.3% upside from $70.90. Recent upgrade from Wells Fargo (Equal Weight to Overweight) signals growing institutional confidence.
Bearish
- High valuation with negative earnings: PS ratio of 8.18x is elevated vs. industry average, and forward PE of 64.24x implies aggressive earnings expectations. If growth decelerates, multiple compression could be severe, as seen in the stock's -79.4% max drawdown.
- Extreme volatility and downtrend: Beta of 1.975 and 1-year price change of -34.56% vs. S&P 500 +22.21% show high risk and underperformance. The stock trades at 28.4% of its 52-week range, indicating persistent selling pressure.
- Revenue concentration in rare disease diagnostics: The company relies heavily on exome/genome sequencing for pediatric rare diseases, a niche market. Any changes in reimbursement policies or competitive entry could disproportionately impact revenue.
- Inconsistent profitability: Despite recent improvement, the company posted a net loss in Q4 2025 and has a history of quarterly losses. Operating margin is still negative at -2.76% (Q3 2025), showing profitability is not yet sustainable.
WGS Technical Analysis
GeneDx's stock has been in a pronounced downtrend over the past year, with a 1-year price change of -34.56%, significantly underperforming the S&P 500's +22.21% gain. The current price of $70.90 sits at approximately 28.4% of its 52-week range (low $32.21, high $170.87), indicating the stock is trading near the lower end of its range, which could suggest either a value opportunity or a falling knife. The stock's beta of 1.975 implies it is nearly twice as volatile as the market, amplifying both upside and downside moves.
Beta
1.98
1.98x market volatility
Max Drawdown
-79.4%
Largest decline past year
52-Week Range
$32-$171
Price range past year
Annual Return
-27.2%
Cumulative gain past year
| Period | WGS Return | S&P 500 |
|---|---|---|
| 1m | +17.5% | +2.4% |
| 3m | +89.1% | +4.6% |
| 6m | -8.6% | +11.7% |
| 1y | -27.2% | +21.4% |
| ytd | -41.7% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WGS Fundamental Analysis
GeneDx's revenue has grown strongly, with Q4 2025 revenue of $120.99 million, up 26.5% year-over-year, and sequential growth from $116.74 million in Q3 2025 and $102.69 million in Q2 2025. The company's gross margin improved to 65.2% in Q4 2025, up from 60.9% in Q2 2024, reflecting better cost management and scale. However, the company remains unprofitable, with a net loss of $17.67 million in Q4 2025, though this loss narrowed from $29.17 million in Q2 2024, and the net margin improved from -41.4% to -14.6% over that period. The balance sheet shows a current ratio of 2.46, indicating strong liquidity, and a debt-to-equity ratio of 0.49, which is moderate. Free cash flow turned positive in recent quarters, with TTM FCF of $14.26 million, suggesting the company is approaching self-sufficiency.
Quarterly Revenue
$120989000.0B
2025-12
Revenue YoY Growth
+26.5%
YoY Comparison
Gross Margin
65.2%
Latest Quarter
Free Cash Flow
$14262000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WGS Overvalued?
Given that GeneDx has negative trailing net income, the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio of 8.18x is elevated compared to the industry average, reflecting the market's high growth expectations. The forward PE of 64.24x implies that analysts expect significant earnings growth, which is consistent with the company's improving profitability trajectory. Historically, GeneDx's PS ratio has ranged from 1.24x in Q4 2023 to 28.91x in Q4 2025, and the current 8.18x is well below the recent high, suggesting the stock may be undervalued relative to its own history if growth continues.
PE
-178.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
534.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's ongoing unprofitability, with a net loss of $17.67M in Q4 2025, though losses are narrowing. The negative operating margin of -2.76% (Q3 2025) indicates that operational efficiency is not yet achieved, and any cost overruns could delay profitability. The debt-to-equity ratio of 0.49 is moderate, but the company's reliance on external funding for growth could lead to dilution if cash flow turns negative again. Revenue concentration in a niche market (pediatric rare diseases) exposes the company to reimbursement policy changes, which could significantly impact revenue growth.
FAQ
The key risks include: 1) Valuation risk: PS of 8.18x and forward PE of 64.24x leave little room for error; 2) Financial risk: ongoing net losses, though narrowing, and negative operating margin; 3) Competitive risk: potential entrants in the exome sequencing market could pressure pricing and market share; 4) Macro risk: high beta of 1.975 makes the stock sensitive to market downturns. The most severe risk is a combination of growth deceleration and multiple compression, which could lead to a -50% drawdown from current levels.
Analysts have a Strong Buy consensus with an average target of $81.78, implying 15.3% upside. The bull case targets $100 (30% probability), the base case $75-85 (50% probability), and the bear case $55-65 (20% probability). The base case is most likely, assuming revenue growth continues around 25% and margins improve. The stock is expected to trade in the $75-85 range over the next 12 months, with potential for higher if the company achieves profitability sooner than expected.
WGS trades at a PS ratio of 8.18x, which is elevated compared to the industry average, but below its historical high of 28.91x. The forward PE of 64.24x implies high growth expectations, which are justified by the company's 26.5% revenue growth and improving profitability. Relative to its own history, the stock is undervalued, but on an absolute basis, it is not cheap. The market is pricing in continued strong growth and margin expansion, so any disappointment could lead to multiple compression.
WGS offers a compelling risk/reward for growth investors, with a Strong Buy consensus and 15.3% upside to the average target of $81.78. The company's revenue growth of 26.5% YoY and improving margins support the bullish thesis. However, the stock is highly volatile (beta 1.975) and trades at a premium valuation (PS 8.18x), so it is not suitable for risk-averse investors. A good buy for those with a long-term horizon and tolerance for drawdowns, but consider waiting for a pullback to below $60 for a better entry point.
WGS is better suited for long-term investment (3-5 years) given its growth stage and volatility. The company is still unprofitable, but its revenue growth and margin expansion suggest a path to profitability that could drive significant upside over time. Short-term trading is risky due to the high beta and price swings, as seen in the -79.4% max drawdown. A minimum holding period of 3 years is recommended to allow the company to execute on its growth strategy and for the market to recognize its value.